Something went wrong with the connection!

Vizag Herald

Chronic Obstructive Pulmonary Disease Pipeline to Witness Many Technological Advancements in the Coming Years

 Breaking News
  • No posts where found

Chronic Obstructive Pulmonary Disease Pipeline to Witness Many Technological Advancements in the Coming Years

May 17
03:20 2017

According to a new research report “Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Chronic obstructive pulmonary disease currently exhibits a pipeline with 65 drug candidates.

Explore Report at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

Chronic obstructive pulmonary disease pipeline in 2017

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates, of which eight drug candidates are in Phase III stage of development, 24 drug candidates are in Phase II stage, nine drug candidates are in Phase I, 22 drug candidates are in Pre-Clinical stage and two drug candidates are in Discovery stage. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. In this condition, lung cells lose their elasticity and get enlarged, which leads to reduction in the amount of gas exchange in the lungs. Sometimes, it progresses to form cancer, stroke and coronary artery disease.

Insights on pipeline segments

As per the findings of the research, around 40.0% of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route, 12.0% are being developed to be administered by oral route, 5.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by intravenous route, 3.0% are being developed to be administered by another route and 37.0% are being developed to be administered by other routes that are undisclosed.

Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development

MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of CNTO6785 for the treatment of chronic obstructive pulmonary disease. The technology platform is used for the in vitro generation of highly specific and fully human antibodies. HuCAL antibodies are produced in bacteria, and the technology enables in vitro selection to isolate antibodies with the desired characteristics. HuCAL is generated by de novo gene synthesis, and the large library is screened with a technique called phage display, to identify the antibody with a high affinity to the investigated antigen.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample

Major companies collaborate for the development of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline

Many companies are involved in the development of drugs for the chronic obstructive pulmonary disease therapeutics pipeline, with their products in different phases. Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc and AstraZeneca plc have their drug candidates in the Phase III stage of development. Adamis Pharmaceuticals Corporation has two drug candidates in Phase II stage of development. Novartis AG also has two drug candidates in Phase II stage of development. Glenmark Pharmaceuticals Ltd. has two drug candidates in Pre-Clinical stage of development.

The research also found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. entered into an agreement with AstraZeneca plc for the exclusive rights of benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease in Asia. In June 2013, AstraZeneca plc acquired Pearl Therapeutics, Inc., which was involved in the development of inhaled small-molecule therapeutics for respiratory disease.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation, Chiesi Farmaceutici S.p.A., Cytokinetics, Inc., Novartis AG and Theravance Biopharma R & D, Inc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY – 10016

Toll-Free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Media Contact
Company Name: P&S Market Research
Contact Person: Kundan
Email: Send Email
Phone: +1-888-778-7886
Address:347 5th Ave. #1402- 210
City: New York City
State: New York
Country: United States
Website: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

Related Articles

Calendar

August 2017
M T W T F S S
« Jul    
 123456
78910111213
14151617181920
21222324252627
28293031